المصدر: Lee J, Zhang W, Moy S, KowalskD, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Kens J. Effects of food take on the pharmacoket properts of mabegron oral controlled-absorptn system: a sgle-dose, randomed, crossover study healthy adults. Cl Ther. 2013 Mar;35(3):333-41. do 10.1016/j.clthera.2013.02.014.
A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00939757Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=632Test

المصدر: Eltk C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meer J, van Marle S, Grunenberg N, KowalskD, Drogendk T, Moy S, tsuka H, van Gelderen M, Matsusha H, Sawamoto T. Sgle dose pharmacokets and absolute bavaaby of mabegron, a beta(3)-adrenoceptor agont for treatment of overacte bladder. t J Cl Pharmacol Ther. 2012 Nov;50(11):838-50. do 10.5414/CP201782.
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00940121Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=659Test

المساهمون: Disclosure Office Europe

المصدر: An Exploratory Study Into the Mechanism of Mirabegron-induced Cardiovascular Effects in Healthy Male Subjects.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01284868Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=634Test

المصدر: Krauwkel W, van Dk J, Schaddelee M, Eltk C, Meer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Pharmacoket properts of mabegron, a beta3-adrenoceptor agont: results from two phase randomed, multle-dose studs healthy young and elderly men and women. Cl Ther. 2012 Oct;34(10):2144-60. do 10.1016/j.clthera.2012.09.010.
An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01285596Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=661Test

المساهمون: Disclosure Office Europe

المصدر: A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01297179Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=640Test

المصدر: An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirabegron in Healthy Young Male and Female Subjects

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01297192Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=666Test

المصدر: Krauwkel W, Dkson J, Schaddelee M, Meer J, Tretter R, van de Weterg J, Strabach G, van Gelderen M. The effect of mabegron, a potent and selecte beta3-adrenoceptor agont, on the pharmacokets of CYP2D6 substrates desrame and metoprolol. Eur J Drug Metab Pharmacoket. 2014 Mar;39(1):43-52. do 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.
An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01478490Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=798Test

المصدر: Eltk C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meer J, van Marle S, Grunenberg N, KowalskD, Drogendk T, Moy S, tsuka H, van Gelderen M, Matsusha H, Sawamoto T. Sgle dose pharmacokets and absolute bavaaby of mabegron, a beta(3)-adrenoceptor agont for treatment of overacte bladder. t J Cl Pharmacol Ther. 2012 Nov;50(11):838-50. do 10.5414/CP201782.
A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01478529Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=680Test

المصدر: Krauwkel W, Dkson J, Schaddelee M, Meer J, Tretter R, van de Weterg J, Strabach G, van Gelderen M. The effect of mabegron, a potent and selecte beta3-adrenoceptor agont, on the pharmacokets of CYP2D6 substrates desrame and metoprolol. Eur J Drug Metab Pharmacoket. 2014 Mar;39(1):43-52. do 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01478568Test

Other URLs: http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=638Test

المصدر: A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01747564Test